• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Liquidia Corporation

    4/24/26 4:20:38 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LQDA alert in real time by email
    DEFA14A 1 tm261471d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No. )

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨ Definitive Proxy Statement
    x Definitive Additional Materials
    ¨ Soliciting Material under §240.14a-12

     

    LIQUIDIA CORPORATION

    (Name of Registrant as Specified In Its Charter)

     

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No fee required.
    ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

    GRAPHIC

    Step 1: Go to www.envisionreports.com/LQDA. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. www.envisionreports.com/LQDA Online Go to www.envisionreports.com/LQDA or scan the QR code — login details are located in the shaded bar below. Liquidia Corporation Stockholder Meeting Notice 049JVA Important Notice Regarding the Availability of Proxy Materials for the Liquidia Corporation 2026 Annual Stockholders Meeting to be Held on June 16, 2026 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2026 proxy statement and 2025 annual report to Liquidia Corporation stockholders are available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before June 5, 2026 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. MMMMMMMMMMMM MMMMMMMMM 000001MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 ENDORSEMENT_LINE______________ SACKPACK_____________ 1234 5678 9012 345 C 1234567890 COY MMMMMMM

    GRAPHIC

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/LQDA. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to investorvote@computershare.com with “Proxy Materials Liquidia” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by June 5, 2026. The 2026 Annual Meeting of Stockholders of Liquidia Corporation will be held on Tuesday, June 16, 2026, 4:30 p.m. Eastern Time, virtually via the internet at meetnow.global/MNVUTUZ. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposals 2 and 3: 1. Election of Directors: 01 - David Johnson 02 - Katie Rielly-Gauvin 03 - Ramandeep Singh 2. To ratify the Appointment of PricewaterhouseCoopers LLP as the Company’s Independent Registered Public Accounting Firm for the Year Ending December 31, 2026. 3. To approve, on an advisory basis, the compensation of our named executive officers. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you. Liquidia Corporation Stockholder Meeting Notice

    Get the next $LQDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LQDA

    DatePrice TargetRatingAnalyst
    10/20/2025$31.00Overweight
    Wells Fargo
    8/15/2025$43.00Buy
    Jefferies
    5/19/2025$13.00Perform → Underperform
    Oppenheimer
    12/20/2024$20.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    8/19/2024Outperform → Strong Buy
    Raymond James
    8/16/2024$27.00Outperform
    Raymond James
    6/25/2024Perform
    Oppenheimer
    More analyst ratings

    $LQDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Caligan Partners Lp bought $317,894 worth of shares (5,300 units at $59.98) and sold $317,894 worth of shares (5,300 units at $59.98) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    5/20/26 8:51:06 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Manning Paul B bought $2,999,994 worth of shares (337,078 units at $8.90) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    9/16/24 4:05:20 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Caligan Partners Lp disposed of 3,440,948 shares, sold $1,426,500 worth of shares (150,000 units at $9.51) and bought $1,426,500 worth of shares (150,000 units at $9.51) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    9/4/24 5:51:34 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Liquidia Technologies with a new price target

    Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $31.00

    10/20/25 8:01:49 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Liquidia Technologies with a new price target

    Jefferies resumed coverage of Liquidia Technologies with a rating of Buy and set a new price target of $43.00

    8/15/25 7:59:34 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Technologies downgraded by Oppenheimer with a new price target

    Oppenheimer downgraded Liquidia Technologies from Perform to Underperform and set a new price target of $13.00

    5/19/25 8:49:50 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Human Resource Officer Krepp Sarah sold $16,800 worth of shares (276 units at $60.87) as part of a pre-agreed trading plan, decreasing direct ownership by 0.19% to 146,743 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    6/3/26 4:31:20 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kirsch Arthur S sold $1,731,300 worth of shares (30,000 units at $57.71) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    6/3/26 4:30:23 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Jeffs Roger sold $399,712 worth of shares (6,428 units at $62.18) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    5/28/26 4:30:13 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

    Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

    11/18/21 2:49:33 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference

    MORRISVILLE, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company's business in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45 p.m. ET. Access to this event will be available on the "Investors" page of Liquidia's website at https://liquidia.com/investors/events-and-presentations. A replay of the webcast will be archived on the company's website for at least 30 days. About Liquidia Corporation Liquidia Corporation is a biopharmaceuti

    5/27/26 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation Reports First Quarter 2026 Financial Results

    YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026Recorded third consecutive quarter of profitability, with net income of approximately $53 million, adjusted EBITDA of $71 million and an increase in cash and cash equivalents by $32 million compared to the fourth quarter of 2025Actively screening PH-ILD patients in Phase 4 Tyvaso® and Tyvaso DPI® transition study and pivotal Phase 3 Re-Spire study of L606 MORRISVILLE, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA),

    5/11/26 6:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation to Participate in Upcoming Investor Conferences

    MORRISVILLE, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced it will participate in upcoming investor conferences. BofA Securities 2026 Health Care ConferenceDate: Wednesday, May 13, 2026 at 8:40 am PTLocation: Las Vegas, NevadaIn addition to hosting one-on-one meetings, Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company's business during a fireside chat beginning at 8:40 am Pacific Time. H.C. Wainwright

    5/6/26 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    SEC Filings

    View All

    SEC Form 144 filed by Liquidia Corporation

    144 - Liquidia Corp (0001819576) (Subject)

    6/4/26 6:38:03 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Liquidia Corporation

    144 - Liquidia Corp (0001819576) (Subject)

    6/4/26 5:24:56 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Liquidia Corporation

    144 - Liquidia Corp (0001819576) (Subject)

    6/1/26 9:56:46 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Liquidia Corporation

    SC 13G/A - Liquidia Corp (0001819576) (Subject)

    11/12/24 5:35:19 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

    SC 13D/A - Liquidia Corp (0001819576) (Subject)

    9/12/24 4:22:57 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

    SC 13D/A - Liquidia Corp (0001819576) (Subject)

    9/4/24 5:51:42 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Financials

    Live finance-specific insights

    View All

    Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026

    MORRISVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its first quarter 2026 financial results on Monday, May 11, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidi

    5/4/26 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and 1,500 patient starts to dateCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on November 3, 2025, to review financ

    11/3/25 6:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

    MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a b

    10/27/25 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Leadership Updates

    Live Leadership Updates

    View All

    Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

    BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

    2/24/25 7:00:00 AM ET
    $AVIR
    $LQDA
    $KDMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

    GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v

    10/2/23 7:00:00 AM ET
    $EBS
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia's new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2022 ("Form 8-K"), Liquidia has agreed to grant Dr. Saggar initial equity awards upon his commencement of employment, which includes a stock option exercisable for 200,000 shares of Liquidia's common stock under the Liquidia Corporation 2022 Inducement Plan (the "Inducement Plan"). The

    7/21/22 4:30:00 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care